* To whom correspondence should be addressed. For J.J.: phone, 919-843-1645; fax, 919-966-0204; E-mail, [email protected]; current address: Center for Integrative Chemical Biology and Drug Discovery, ...

Molecular Signaling Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892, United States ...

Muscarinic acetylcholine receptors consist of five distinct subtypes and have been important targets for drug development. In the periphery, muscarinic acetylcholine receptors mediate cholinergic ...

Contributed by J. Andrew McCammon, July 27, 2016 (sent for review June 24, 2016; reviewed by Richard J. Lewis and Jung-Hsin Lin) ...

Muscarinic receptors are involved with neurotransmission ... Leaving out activity against M2 and M3 receptors could also improve the safety and tolerability of the drug, by avoiding unwanted ...

NBI-1117568 is the first and only investigational oral muscarinic M4 selective orthosteric agonist in clinical development as a potential treatment for schizophrenia. These results were shared as an ...

(NASDAQ:NBIX) has announced promising results from its Phase 2 trial of NBI-1117568, a first-in-class investigational oral muscarinic M4 selective agonist for schizophrenia. Presented at the ...

Karuna filed KarXT for approval in the US last month and is waiting for a verdict from the FDA on the drug – which combines muscarinic agonist xanomeline tartrate and muscarinic antagonist ...

The company develops NBI-1117568, a muscarinic M4 agonist in phase 2 trial for schizophrenia and other neuropsychiatric disorders; and ORX750, an OX2 agonist in phase 2 trial for narcolepsy and ...

NBI-1117568 is the first and only investigational oral muscarinic M4 selective orthosteric agonist in clinical development as a potential treatment for schizophrenia. These results were shared as ...